Calle Serrano Vaccino contro il cancro alla prostata. Research Organisations. Vaccino contro il cancro alla prostata web. Contatto amministrativo. Numero 76, Ottobre Il cancro alla prostata rappresenta uno dei tumori più comuni diagnosticati negli uomini in tutto il mondo. Lo sfruttamento del sistema immunitario per combattere il cancro è stato esplorato per anni con approcci immunoterapici, impiegando un certo numero di vaccino contro il cancro alla prostata, cellule immunitarie ingegnerizzate, antigeni o persino cellule tumorali intere come vaccini.
Juan Padrón. Un nuovo approccio per stimolare il sistema immunitario I TLR rappresentano un costituente centrale del sistema immunitario in quanto sono espressi sulle cellule immunitarie innate e contribuiscono a riconoscere gli agenti patogeni intrusivi. Padrón e il dott. Pedro Miranda. La logica era quella di ingannare i macrofagi nel pensare che la cellula del cancro alla prostata sia un batterio, affinché la uccidano.
Per generare il linker, i ricercatori hanno sviluppato con successo una nuova via sintetica che accelera il processo consentendo anche di incrementare la reazione. Il processo generale di sintesi del vaccino si basa su semplici tecniche di purificazione che vaccino contro il cancro alla prostata la produzione di una quantità massima di 1 grammo di composto.
Il futuro dei vaccini per la prostata Tradizionalmente, il cancro alla prostata viene trattato con una terapia farmacologica, ma la maggior parte dei pazienti recidiva e soccombe alla malattia.
La notevole scoperta del Vaccino contro il cancro alla prostata negli ultimi anni ha aperto nuove strade per la terapia del cancro alla prostata. I vaccini anti-cancro hanno ricevuto grande attenzione nel corso degli anni, tuttavia hanno ottenuto pochissimi risultati clinici.
La prevenzione della recidiva di malattie potenzialmente fatali mediante sollecitazione del sistema di difesa immunitario del proprio corpo è vaccino contro il cancro alla prostata impegno continuo. Una migliore comprensione di come funziona il sistema immunitario contribuirà indubbiamente a trovare una cura per vari tipi di cancro, salvando milioni di vite e riducendo i costi sanitari.
Dualità tra esigenze della sanità pubblica e interessi economici nel mercato farmaceutico nel Sud del mondo. Livellare le correnti ascensionali: una ricerca getta nuova luce sulla dinamica della turbolenza.
Il monitoraggio in tempo reale basato su cloud a casa farà cantare il cuore. Risultati finali non disponibili. Autori: Miranda, Pedro O. Editore: ACS Publications Vaccino contro il cancro alla prostata permanente: doi Editore: American Chemical Society Autori: Pérez, Sixto J.
English EN. Scheda informativa. Risultato in breve. The project will consist of the design, synthesis and biological evaluation of synthetic vaccines that will chemically stimulate the toll-like receptors and therefore create an immune response. During the return phase, Miranda will integrate his research findings into the studies carried out by the research group at IPNA. The return of knowledge and skills to the Canary Islands, Spain, will take place vaccino contro il cancro alla prostata a time when there is an increasing support from the government and also European authorities for the development of the Canary Islands as a nerve center in Biomedical studies through research programs partially financed by European funding.
Tipo di attività Research Organisations. Stato Progetto concluso. Data di avvio 5 Gennaio Data di completamento 4 Gennaio Un nuovo vaccino contro il cancro alla prostata Il cancro alla prostata rappresenta uno dei tumori più comuni diagnosticati negli uomini in tutto il mondo.
Scopri altri articoli nello stesso settore di applicazione. Immune cells scan tissues with the objective of vaccino contro il cancro alla prostata newly malignant cells before they turn into fully formed tumors. Innate immune cells recognize the intruding pathogen and trigger appropriate immune response with the help of Toll-Like receptors.
They are expressed in sentinel cells such as macrophages and therefore they are responsible for the macrophage activation and control of parasitic infections. Among all the Toll family receptors, TLR4 recognizes a wide array of ligands, including lipopolysaccharide LPS a cell wall component of Gram-negative bacteria, responsible for macrophage activation and signal transduction. In recent years there has been evidences indicating that mutations in TLR4 were associated with risk of prostate cancer.
Prostate cancer represents one of the most common cancers diagnosed in males in the Western countries. Vaccino contro il cancro alla prostata pharmacological therapy, consisting of ablation of androgens, is initially efficient, but most treated patients progressively develop the disease again and eventually die of cancer. Consequently, many efforts are being made to identify novel targets and agents useful for the treatment of this disease. A notable discovery in recent years has been the identification of an over-expressed protein in the surface of the prostate cancer cells, namely, prostate specific membrane antigen PSMA.
Thus, designing a bifunctional linker carrying a small molecule PSMA binder on one side and a weak agonist on the other side would allow the macrophages to sense it thinking to be a bacterium and kill the dispensable tissue. However, due to the high complexity of it, different strategies in order to perform the synthesis had to be explored.
Synthesis of PSMA inhibitor were carried out using the urea based approach, while the agonist derived from monophosphoryl lipid A was synthesized using the proposed approach. The dipeptide PSMA approach was not successful due to the instability of the diazo group, which was light sensitive and not stable. In fact, it decomposed after few minutes of being synthesized. Once the molecule was obtained, during the second year stability studies were performed using human serum followed by binding studies to prostate cancer cells.
Also, binding studies have been carried out in order to show the efficacy of the compound. Cell proliferation assays were performed to check the suitability in its inhibition of cancer cells. Finally, IC50 values were measured using the Naaladase Assay. Stability of the product has been tested in human serum at 3 micromolar in concentration, showing its degradation after 18 hrs, which points out its stability in serum.
Moreover, the expression and purification of the PSMA protein allowed us to study by NMR its interaction with the protein showing its efficacy.
Synthesis of the dipeptide inhibitor as well as the urea based inhibitor was made. While the dipeptide inhibitor was synthesized according to what was previously reported, in the case of urea based inhibitors slight modifications were made in order to assure its efficacy when making in vitro assays. To it, it was added a maleimide and aromatic moieties that will allow the PSMA to bind and remain fixed on vaccino contro il cancro alla prostata surface of the prostate cancer cell.
On the other hand, the synthesis of the agonist was carried out as it was planned. Final purification of the molecule using reverse phase techniques was performed in order to achieve a reliable purity of the compound.
Stability assays of the final molecule were carried out in human serum at a concentration of 3 micromolar. A portion of it was degraded after 18 hrs, which clearly shows enough stability of the molecule. Binding vaccino contro il cancro alla prostata studies were performed using both positive and negative PSMA cells. Following the procedure described in Annex I we got a preliminary binding constant of 8 nM, which considerably enhances the previous results reported in literature.
We carried out a Naaldase Assay in order to get IC50 values for the compound. However, no significant results have been observed using this technique. PSMA protein was expressed and purified following standard protocols, and the binding of the protein with the molecule was checked by NMR techniques, showing its efficacy.
Cell proliferation assay was carried out. This showed an important inhibition of the PSMA positive cells, which constitutes a promising result of the utility of the product. Attempts to vaccino contro il cancro alla prostata animal models are currently under way. Kim D. Janda, Dr. Miranda has complemented his expertise in basic design of vaccines, being trained in the use of new techniques such as: - Surface Plasmon Resonance and Isothermal titration calorimetry which are widely used in the measurement of binding constants.
This technique was used to detect the binding affinity of the PSMA antigen. With this new synthetic route, we can skip up to 4 steps comparing with other different synthesis published in literature. Moreover, an important difference from the reported procedures in literature is the possibility of scaling up the amount of material needed.
Thus, we have been able to synthesize up to 1 gr of target molecule, which constitutes an important outbreak in order to proceed and make in vivo experiments. In vitro stability experiments have shown that product was degraded after 18 hrs incubation at 37 C in human serum. In accordance with this result, the final compound was regarded as being stable. Prostate cancer is the second most common cancer worldwide for males, and the fifth most common cancer overall.
Within the 27 countries of the European Union, prostate vaccino contro il cancro alla prostata has emerged as the most frequent cancer amongst men, with increasing rapidly over the past two decades.